News

Luxembourg Parkinson’s Study Awarded €6M From FNR for Second Phase

Continuing its support of a collaborative Parkinson’s disease (PD) study, the Luxembourg National Research Fund (FNR) has awarded the National Centre for Excellence in Research on Parkinson’s Disease (NCER-PD) €6 million ($6.68 million) for its second phase. Comprised primarily of five research partners, the four-year-old Luxembourg-based NCER-PD is…

Imbalance in Dopamine and Acetylcholine Levels May Drive Disease Progression, Study Finds

Therapies against motor loss and progression in Parkinson’s’ disease (PD) may need to tackle the imbalance between two neurotransmitters, dopamine and acetylcholine, instead of focusing on dopamine alone, an early study suggests. The study, “Dopamine Deficiency Reduces Striatal Cholinergic Interneuron Function in Models of Parkinson’s Disease,” was published…

Bacteria in Gut Can Promote Parkinson’s by Altering Brain’s Immune Reactions, Study Says

Bacterial infections in the intestines may trigger Parkinson’s progression by altering the immune system and damaging dopaminergic neurons, according to an early study supporting a “gut-brain” connection in this disease. The findings, “Intestinal infection triggers Parkinson’s disease-like symptoms in Pink1−/− mice,” were published as a letter in…

N-acetylcysteine Helps Ease Motor, Cognitive Problems in PD, Study Reports

Treatment with the naturally occurring antioxidant N-acetylcysteine (NAC) along with standard Parkinson’s therapies improved patients’ motor and mental abilities, possibly by restoring the function of dopamine-producing nerve cells, according to new research. The study, “N-Acetyl Cysteine Is Associated With Dopaminergic Improvement in Parkinson’s Disease,” appeared in…